Artrya (AYA) H2 2026 earnings summary

Executive summary

• Transitioned to first full year of commercial operations, securing three U.S. foundation customers and generating initial U.S. commercial revenues.

• Achieved FDA clearance for SalixⓇ Coronary Plaque module, expanding clinical and commercial opportunities.

• Completed $80 million capital raise to fund U.S. commercialisation and operational scale-up.

• Launched SAPPHIRE Study with six major U.S. health systems to build clinical evidence and accelerate adoption.

• Strengthened U.S. commercial infrastructure and leadership team to support growth.

Financial highlights

• Reported revenue remained flat at $28,000, with SaaS revenue (before non-cash adjustments) increasing to $177,000 from $28,000 year-over-year.

• Operating loss increased 53.5% to $25.18 million (2025: $16.41 million), including $5.9 million in non-cash expenses related to partner affiliate options.

• Cash balance at year-end was $44.0 million, with an additional $30.1 million in term deposits.

• Net assets rose to $78.3 million from $21.3 million year-over-year.

• No dividends declared or paid for the year.

Outlook and guidance

• Focus for FY2027 is to deepen adoption within existing customers, expand to new health systems, and secure FDA clearance for SalixⓇ Coronary Flow.

• Continued investment in product development, clinical evidence, and customer success to drive long-term growth.

• SAPPHIRE Study expected to generate data for publication and support broader market adoption.